GB201 + paclitaxel + gemcitabine

A combination therapy consisting of **GB201**, **paclitaxel**, and **gemcitabine** is under clinical investigation for the treatment of metastatic pancreatic cancer following standard chemotherapy failure. GB201 is an investigational agent whose precise molecular identity and mechanism of action are not fully disclosed in public sources as of September 2025. Paclitaxel is a microtubule-stabilizing agent (taxane class) that inhibits cell division, while gemcitabine is a nucleoside analog that inhibits DNA synthesis; both are established chemotherapies with broad anticancer activity. This combination regimen is being evaluated in Phase II/III clinical trials as second-line or later therapy for patients with metastatic pancreatic adenocarcinoma[3][5].